Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

COCOON DM Regimen Reduces Amivantamab/Lazertinib Effects on QOL in EGFR-Mutated NSCLC

June 2nd 2025

COCOON DM reduced the severity and QOL influence of dermatologic AEs vs SOC DM in EGFR-mutant, advanced NSCLC treated with amivantamab plus lazertinib.

Perioperative Nivolumab Sustains EFS Advantage in Resectable NSCLC, With Enriched Benefit in ctDNA–, pCR Responders

June 2nd 2025

Neoadjuvant chemotherapy and nivolumab and adjuvant nivolumab prolonged EFS vs placebo in patients with resectable NSCLC in follow-up from CheckMate-77T.

LB2102 CAR T-Cell Therapy Is Well Tolerated, Yields Disease Control in R/R SCLC and LCNEC

June 2nd 2025

The DLL3-directed CAR T-cell therapy LB2102 was safe with preliminary antitumor activity in small cell lung cancer and large cell neuroendocrine carcinoma.

Neoadjuvant Alectinib Yields Responses in Late-Stage, Potentially Resectable ALK+ NSCLC

June 2nd 2025

Neoadjuvant alectinib produced major pathologic responses, and it was tolerable and feasible in potentially resectable, stage III, ALK-positive NSCLC.

Addition of Toripalimab to Induction Improves PFS in Nonresectable NSCLC

June 2nd 2025

Adding induction toripalimab to chemotherapy followed by definitive chemoradiotherapy and consolidation therapy reduced risk for disease progression by 74%.

Sacituzumab Tirumotecan Yields Superior Clinical Activity in EFGR+ NSCLC

June 1st 2025

Sacituzumab tirumotecan showed statistically significant improvements in responses and survival vs docetaxel alone in advanced EGFR-mutant NSCLC.

Patritumab Deruxtecan Does Not Improve Overall Survival in EGFR-Mutated NSCLC

June 1st 2025

Patritumab deruxtecan did not improve OS vs platinum-based chemotherapy in patients with EGFR mutation–positive locally advanced or metastatic NSCLC.

Savolitinib Plus Osimertinib Hits PFS End Point in EGFR-Mutated, MET-Amplified NSCLC After Disease Progression With an EGFR TKI

June 1st 2025

Savolitinib plus osimertinib was safe and effective in patients with EGFR-mutated, MET-amplified advanced NSCLC after disease progression on an EGFR TKI.

Sevabertinib Induces Durable Response in Advanced HER2-Mutant NSCLC

June 1st 2025

Treatment with the oral TKI showed promising responses among 2 subgroups of patients with advanced, HER2-mutant non–small cell lung cancer.

Dr Spigel on Adjuvant Chemotherapy in Stage IA/IIA, Molecularly Higher-Risk NSCLC

June 1st 2025

David Spigel, MD, discusses evaluating the utility of adjuvant chemotherapy in patients with stage IA to IIA NSCLC identified as high risk by a 14-gene molecular assay.

Adagrasib Plus Pembrolizumab Generates Responses in KRAS G12C+ NSCLC

June 1st 2025

Adagrasib plus pembrolizumab was efficacious in patients with KRAS G12C-mutant NSCLC.

Amivantamab Plus Chemo Maintains PFS Benefit in EGFR+ NSCLC Regardless of Osimertinib Resistance Mechanism

May 31st 2025

Amivantamab/chemotherapy demonstrated sustained efficacy, despite the osimertinib resistance mechanism in patients with EGFR-mutated NSCLC.

Dr Califano on MARIPOSA-2 Outcomes by Baseline Resistance Mechanisms in EGFR+ NSCLC

May 31st 2025

Raffaele Califano, MD, discusses molecularly stratified outcomes amivantamab with chemotherapy vs chemotherapy alone in patients with advanced EGFR-mutant NSCLC.

Adjuvant Chemotherapy Improves DFS in Molecularly Higher-Risk NSCLC

May 31st 2025

Adjuvant chemotherapy generated a DFS benefit over observation in patients identified as having higher-risk nonsquamous NSCLC per a prognostic assay.

Revisit Every OncLive On Air Episode From May 2025

May 30th 2025

Read a recap of the episodes of OncLive On Air that debuted in May 2025.

Novel Treatment Approaches Under Investigation in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on novel approaches being investigated in ROS1-positive non–small cell lung cancer.

Another FDA-Approved Option? The Potential Role for Taletrectinib in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on how FDA approval of taletrectinib would affect ROS1-positive non–small cell lung cancer management.

Pooled Data for Taletrectinib in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss data for taletrectinib in ROS1-positive non–small cell lung cancer.

Addressing CNS Involvement in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss CNS involvement in ROS1-positive non–small cell lung cancer.

Selecting a TKI in ROS1+ NSCLC Management

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss TKI selection in ROS1-positive non–small cell lung cancer.